INTRODUCTION
Psoriasis is a chronic immune-mediated inflammatory skin disease [1, 2] , with plaque psoriasis accounting for more than 80-90% of cases [1, 3] . Plaque psoriasis appears as well-defined, well-demarcated, erythematous plaques [1] . Psoriasis is one of the most common inflammatory diseases of the skin, with an estimated prevalence in Western countries of between 0.6% and 4.8% [4] [5] [6] [7] .
Notably, results of a recent study suggest that the incidence of the disease in adults has been steadily increasing [2] . Psoriasis is commonly categorized as mild, Epidemiological studies show that about 25% of patients have moderate-to-severe forms of the disease [10] . Moderate-to-severe psoriasis is associated with significant comorbidity [3, 11, 12] and has been shown to severely impair quality of life (QoL) of affected patients [3, [13] [14] [15] . Moreover, psoriasis is associated with high costs, including those associated with treatments. These costs have increased recently, as the treatment options for psoriasis have expanded to include biological systemic agents, most recently secukinumab [16, 17] . However, despite clear evidence of their value in the treatment of moderate-to-severe plaque psoriasis, access to these agents remains limited to centers originally involved in the Psocare network in Italy.
Objective and Methodology
The aim of this review was to present an overview of the current epidemiological data, the clinical and socioeconomic burden of moderate-to-severe psoriasis and its comorbidities, and available treatments in the context of current treatment guidelines and access to treatment. This is a narrative review and so a systematic search strategy was not performed. Ad hoc literature searches were carried out to find the most recent and relevant data and guidelines on this topic.
Additional information came from a meeting of an Italian advisory board, which included a pharmacoeconomics expert, clinical dermatologists, and hospital pharmacists, convened to define the impact in terms of organization, management, and costs of secukinumab for the treatment of patients with moderate-to-severe plaque psoriasis who are eligible for systemic therapy. This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.
BURDEN OF DISEASE
Psoriasis is associated with a substantial burden, due to significant comorbidity, severe impact on QoL, and high costs, both direct and indirect. It is a chronic disease, for which there is no cure and hence patients need lifelong care.
Comorbidities
Patients with psoriasis are likely to suffer from comorbidities such as psoriatic arthritis (approximately 20%) [12] . Moreover, 50% of patients suffer from fingernail psoriasis and 35% from toenail involvement [18] . Psoriasis has also been shown to be associated with a number of other chronic inflammatory conditions, thought to be due to common pathogenic mechanisms. More specifically, the incidence of inflammatory bowel disease is higher in patients with psoriasis than in the general population [18] [19] [20] , and there is a suggested link between multiple sclerosis and psoriasis, as psoriasis is more common in those with multiple sclerosis than in control subjects [21] .
Patients with psoriasis are more likely to be overweight, have diabetes, hypertension and dyslipidemia, and often have metabolic syndrome, with an associated increase in risk of cardiovascular morbidity and mortality [3, 18, [22] [23] [24] [25] [26] [27] . Additionally, patients with psoriasis are at increased risk of stroke [28] and myocardial infarction [29] . Importantly, mortality associated with myocardial infarction or stroke is 2.6-times higher in patients with early and frequent hospital admissions for psoriasis [30] . Severe psoriasis has also been shown to be associated with an increase in overall mortality risk (hazard ratio 1.5; 95% confidence interval 1.3-1.7) [31] , as well as reduced life expectancy [31] .
Psoriasis also has a significant psychological and emotional impact on patients and is associated with an increased incidence of mood disorders such as anxiety and depression [11, [32] [33] [34] . As many as 60% of psoriasis patients receive a diagnosis of depression [11] , and psoriasis has also been found to be associated with suicidal ideation [33] .
Quality of Life
Studies have shown that the impairment of health-related QoL (HRQoL) in patients with psoriasis is comparable with that due to hypertension, diabetes, cancer, depression, and heart disease [3, 13, 15, 35] . The negative impact of psoriasis on patient QoL can be attributed to the fact that it interferes with many day-to-day activities, activities related to work/school and leisure time, and impacts interpersonal and social relations [14] . Disease symptoms such as itching and pain can interfere with ordinary day-to-day activities such as washing, dressing, and sleeping, and psoriasis on the hands and feet can hinder many activities of daily living [36] .
A study performed in Italy in 11 centers of the Psocare program showed that at least 50% of the assessed patients reported a minimum 20% decrease in their QoL related to their health state [15] . Factors associated with these decreases in QoL include frequent medical appointments, hospitalization, missing work, and reduced productivity [37] . The most important determinants of the impact of psoriasis on HRQoL are the sites affected and patients' attitude to their condition [13] . QoL reduction is greater if visible areas, the soles of the feet, and nails are involved [38] [39] [40] [41] . Unfortunately, stigmatization is frequently experienced by patients with psoriasis, with associated reductions in QoL [42, 43] .
Cost Burden
Psoriasis has high direct, indirect, and intangible costs-the more severe the disease the higher the costs [44] . Direct costs of psoriasis include those related to prescription drugs, hospital admissions, medical examinations, phototherapy, laboratory tests, and the costs of the over-the-counter products [45] . The indirect costs associated with psoriasis include those related to reduced work productivity, due to days of work missed because of the disease, and the time required for medical examinations and non-pharmacological treatments, such as phototherapy and prescribed diagnostic procedures [45] . Key cost drivers in psoriasis include costs due to hospitalization, pharmaceutical products, and physician visits.
Patients with the most severe psoriasis account for a disproportionate amount of total psoriasis costs [46] . Additionally, psoriasis has been shown to have a significant impact on productivity and income [47, 48] , and more than half of all patients with psoriasis report missing an average of 26 days of work per year [47] .
Costs associated with psoriasis are high worldwide, indicating a continued need for treatments that offer good value for money. In 2004, the annual total cost (direct and indirect) of psoriasis in the US alone was approximately US$1.40 billion [49] . Among European countries, recent studies reported annual total costs per patient of €11,928 in Sweden [50] , €8372 in Italy [45] , and €2866-6707 in Germany [51] ; this cost was estimated to be CDN$7999 in Canada [52] .
TREATMENT
The therapeutic approach to psoriasis depends on disease severity. for secukinumab as first-line systemic treatment of moderate-to-severe plaque psoriasis patients [16, 17] . Secukinumab is a first-in-class fully human anti-interleukin (IL)-17 monoclonal antibody [59] [60] [61] . Secukinumab targets the IL-17A ligand and acts by inhibiting the interaction of the IL-17A ligand with its receptor, which is expressed on various cell types [60] . This inhibits release of pro-inflammatory cytokines, chemokines, and mediators of tissue damage, reducing IL-17A-mediated processes involved in autoimmune and inflammatory diseases such as psoriasis. Secukinumab is the first biological drug approved for the first-line treatment of patients eligible for systemic therapy; all other available biological agents for psoriasis are approved as second-line systemic therapy.
The efficacy of secukinumab for moderate to severe plaque psoriasis is supported by the findings of the ERASURE (n = 738) and FIXTURE (n = 1306) trials (ClinicalTrials.gov identifiers: NCT01365455 and NCT01358578, respectively), both of which were 52-week phase [62] . In these trials, secukinumab was given as a 300-mg or 150-mg dose once weekly for 5 weeks, then once every 4 weeks. Secukinumab was superior to placebo for the co-primary endpoints of C75% reduction in PASI (PASI 75) and a score of 0 or 1 on a 5-point modified investigator global assessment scale ( Table 2) . Two additional placebo-controlled randomized trials, JUNCTURE (n = 182) [63] and FEATURE (n = 177; ClinicalTrials.gov identifiers: NCT01636687 and NCT01555125, respectively) [64] , evaluated the efficacy of secukinumab 300 mg or 150 mg administered with an autoinjector or prefilled syringe on moderate to severe psoriasis. In these trials, secukinumab was given once weekly up to week 4, then every 4 weeks, with findings again supporting the efficacy of secukinumab (Table 2) .
Importantly, in the FIXTURE trial the efficacy of secukinumab was compared with etanercept, and it was found that secukinumab was significantly more effective than subcutaneous etanercept 50 mg administered twice weekly with respect to the co-primary efficacy end points of PASI 75 and a response of 0 or 1 on the modified investigator's global assessment at week 12 [62] . Furthermore, the 
Cost Effectiveness of the Biological Agents
Biologicals are an important option in moderate-to-severe plaque psoriasis, but are associated with significant costs and are a considerable strain for the national health systems (NHSs) of various countries. For this reason, many countries have strict criteria for refunding the cost of biologicals. In Italy the expenditure for biologicals used in psoriasis, rheumatic diseases, and oncology represents 13.7% of the drug expenditure for the NHS [37] .
Various estimates of annual costs of these therapies have been found to range between US$13,000 and US$30,000 in one study [73] , with a more recent study providing estimates of annual treatment costs with biological agents ranging from US$6800 for low-dose alefacept (no longer marketed) to US$56,000 for high-dose ustekinumab [74] . Another study estimated the cost of 1 year of induction and maintenance treatment to be as follows: ustekinumab US$53,909; etanercept US$46,395; and adalimumab US$39,041 [75] .
In a recent review of data from high-quality randomized trials (n = 27), cost-effectiveness ratios (determined over a 12-week period) were calculated as cost per patient achieving a PASI 75 response and the cost per patient achieving the minimal important difference in the DLQI score [74] . In this study, intravenous infliximab 3 mg/kg was the most cost-effective biologic agent (Table 3 ). Although costs of biologics are higher, adherence rates are better and patients require fewer hospitalizations with biologic therapy versus non-biologics; a longitudinal cohort study of 186 patients with psoriasis in the US showed that adherence rates were 0.66 with biologics versus 0.35 with other psoriasis medications (P\0.001), and the mean number of hospitalizations was reduced from 0.9 in the 6 months before starting biologics to 0.4 in the 6 months after patients started therapy with biologics (P\0.001) [76] .
Italian-based studies have shown that hospitalization costs constitute a significant proportion of total costs; in one study, hospitalization costs were [80% of total costs, and more than 90% of the cost of physician visits, day hospital stays, and hospitalizations were incurred by the 20% of patients who were hospitalized [77] . In another study of Italian Ustekinumab is recommended for patients with severe plaque psoriasis not responding to, intolerant of, or with contraindications to standard systemic therapies, although it is noted that no robust differences in cost effectiveness between adalimumab and ustekinumab have been shown [82] . Notably, if etanercept is given continuously, rather than intermittently, ustekinumab is, in comparison, less costly and more effective. 
The Italian Situation

Access to Biologicals for Psoriasis in Italy
There is a substantial body of evidence demonstrating the value of using effective therapies for psoriasis. Biologicals have changed psoriasis treatment standards, not only effectiveness, but in allowing the management of patients in an out-patient setting. However, the biological therapies are expensive. In the Italian NHS, biological drugs amount to €30.1 per capita (13.7% of the Italian NHS pharmaceutical expenditure), with biological agents for psoriasis representing 28.9% of the expenditure for biologic drugs [37] . 
Impact of Secukinumab Entry on the Market
The entry of secukinumab among first-line This could be achieved by collaboration between scientific societies and patient associations. This is of particular importance
given the current lack of interest from decision-makers and the public regarding the impact of psoriasis on patient QoL. Moreover, the excellent results seen for secukinumab using the reduction of PASI of at least 90% (PASI 90) as an efficacy measure may lead to this becoming the new standard of effectiveness for agents useful for the treatment of psoriasis, although many physicians at present are happy with achievement of PASI 75.
However, there are a number of potential hurdles for secukinumab to overcome in Italy so that it reaches its full potential in the treatment of moderate-to-severe psoriasis. An important potential weakness of secukinumab in terms of access to the drug is the possibility that it could be subject to prescribing restrictions. In Italy, sofosbuvir, used in the treatment of chronic hepatitis C, is subject to 
